Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 14/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872177 | 1.00 | DGAT1 (0.58) | DGAT1USP2MAPTTDP1PDE4D | |
| SCHEMBL13664077 | 0.91 | DGAT1 (0.68) | DGAT1 | |
| SCHEMBL19292677 | 0.91 | DGAT1 (0.68) | DGAT1 | |
| SCHEMBL14617030 | 0.91 | DGAT1 (0.68) | DGAT1 | |
| SCHEMBL180819 | 0.91 | DGAT1 (0.68) | DGAT1 | |
| SCHEMBL15872159 | 0.90 | DGAT1 (0.67) | DGAT1 | |
| Potassium Ion SCHEMBL15872163 | 0.89 | DGAT1 (0.58) | DGAT1PDE4DPDE10ANPC1ALDH1A1 | |
| SCHEMBL15872161 | 0.89 | DGAT1 (0.58) | DGAT1PDE4DPDE10ANPC1ALDH1A1 | |
| Potassium Ion SCHEMBL15872162 | 0.89 | DGAT1 (0.58) | DGAT1PDE4DPDE10ANPC1ALDH1A1 | |
| SCHEMBL15872172 | 0.89 | DGAT1 (0.58) | DGAT1PDE4DPDE10ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943488-B1 | MEGLUMINE SALT FORMS OF 2-((1 R,4R)-4-(4-(5-(BENZOXAZOL-2-YLAMINO)PYRIDIN-2-YL)PHENYL)CYCLOHEXYL) ACETIC ACID AND THEIR USE AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| EP-2402319-B1 | DGAT Inhibitors | NOVARTIS AG (CH) | 2017-08-30 | — | — | EP | disclosed |
| US-9242971-B2 | Compounds for the treatment of conditions associated with DGAT1 activity | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2943488-A1 | MEGLUMINE SALT FORMS OF 2-((1 R,4R)-4-(4-(5-(BENZOXAZOL-2-YLAMINO)PYRIDIN-2-YL)PHENYL)CYCLOHEXYL) ACETIC ACID AND THEIR USE AS DGAT1 INHIBITORS | Novartis AG (CH) | 2015-11-18 | — | — | EP | disclosed |
| US-20150166522-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8987459-B2 | Compounds for the treatment of conditions associated with DGAT1 activity | NOVARTIS AG (CH) | 2015-03-24 | — | — | US | disclosed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20140200246-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | NOVARTIS AG (CH) | 2014-07-17 | — | — | US | disclosed |
| EP-2418202-A1 | New compounds | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2404905-A1 | New compounds | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2402319-A1 | DGAT Inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402318-A1 | DGAT inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402317-A1 | DGAT inhibitor | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885USP2 3633/4885MAPT 1739/4885 |
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885USP2 3633/4885MAPT 1739/4885 |
| US-20140200246-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | DGAT1, DGAT2, GBA1 | DGAT1 1/4885USP2 3268/4885MAPT 647/4885 |
| US-20150166522-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | DGAT1, DGAT2, GBA1 | DGAT1 1/4885USP2 3268/4885MAPT 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.